Bellicum Pharmaceuticals Inc (BLCM) Director Jon P. Stonehouse Buys 10,000 Shares of Stock

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Director Jon P. Stonehouse bought 10,000 shares of Bellicum Pharmaceuticals stock in a transaction on Friday, November 9th. The stock was acquired at an average price of $4.56 per share, for a total transaction of $45,600.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $45,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

NASDAQ:BLCM opened at $4.21 on Wednesday. Bellicum Pharmaceuticals Inc has a 52 week low of $3.92 and a 52 week high of $10.40. The company has a current ratio of 8.01, a quick ratio of 8.01 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $180.82 million, a price-to-earnings ratio of -1.48 and a beta of 1.06.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.03. The firm had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.07 million. On average, research analysts predict that Bellicum Pharmaceuticals Inc will post -2.39 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA grew its stake in shares of Bellicum Pharmaceuticals by 161.4% in the second quarter. BNP Paribas Arbitrage SA now owns 16,949 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 10,466 shares in the last quarter. Swiss National Bank grew its stake in shares of Bellicum Pharmaceuticals by 32.3% in the second quarter. Swiss National Bank now owns 58,600 shares of the biopharmaceutical company’s stock valued at $432,000 after buying an additional 14,300 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Bellicum Pharmaceuticals in the third quarter valued at $110,000. Virtu Financial LLC grew its stake in shares of Bellicum Pharmaceuticals by 266.8% in the third quarter. Virtu Financial LLC now owns 38,673 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 28,131 shares in the last quarter. Finally, DAFNA Capital Management LLC acquired a new stake in shares of Bellicum Pharmaceuticals in the second quarter valued at $221,000. 59.33% of the stock is owned by institutional investors and hedge funds.

A number of research firms have commented on BLCM. BidaskClub upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. ValuEngine upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 22nd. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research report on Friday, November 9th. Cantor Fitzgerald set a $18.00 target price on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. Finally, Citigroup reduced their target price on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $13.42.

WARNING: This piece was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/11/14/bellicum-pharmaceuticals-inc-blcm-director-jon-p-stonehouse-buys-10000-shares-of-stock.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.

Featured Story: Closed-End Mutual Funds (CEFs)

Insider Buying and Selling by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply